Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions.
The effect was studied of four different synthetic progestins (Org 30659, gestodene, 3-ketodesogestrel and levonorgestrel) on the proliferation of the 17 beta estradiol (E2)-dependent human breast cancer cell line MCF7. All progestins were found to stimulate proliferation, but only at high pharmacological dosages. Moreover, like estrogens the progestins at high concentrations synergistically stimulated MCF7 cell proliferation together with low concentrations of insulin. This stimulatory effect could be blocked by antiestrogens, but not by antiglucocorticoids and antiprogestins. This suggests that growth stimulation by these progestins (or their metabolites) occurs through crossreaction with the E2 receptor (ER). This is confirmed by the observation that the strong synthetic progestin Org 2058 does not stimulate proliferation. The absence of a progesterone receptor (PR)-mediated growth response seems not to be due to aberrant PR expression in these cells; 27,000 receptors (Kd 1.7 x 10(-10)M) per cell were present under growth-assay conditions. Growth stimulation by E2 in the absence or presence of insulin, is slightly inhibited or unaffected by the progestins, respectively. Our data do not support a role for the recently identified gestodene binding sites [Colletta et al., J. Steroid Biochem. 33 (1989) 1055-1061] in mediating gestodene effects on breast cancer cells: gestodene and 3-ketodesogestrel, a compound that does not bind to these gestodene binding sites, showed a similar biological activity. The effects of the progestins on the MCF7 breast cancer cell line, indicate that the use of these compounds at very high concentrations may be unfavourable, but do not support a role for them in directly stimulating breast tumor proliferation at the low progestin concentration which are reached in the serum in oral contraceptive users.
van der Burg
B
B
Hubrecht Laboratory, Netherlands Institute for Developmental Biology, Utrecht.
Kalkhoven
E
E
Isbrücker
L
L
de Laat
S W
SW
D000704:Analysis of Variance; D001943:Breast Neoplasms / Q000139:chemically induced / Q000473:pathology*; D002455:Cell Division / Q000187:drug effects*; D003276:Contraceptives, Oral / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D004967:Estrogens / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D007328:Insulin / Q000502:physiology; D009652:Norpregnenes / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D003276:Contraceptives, Oral; D004967:Estrogens; D006133:Growth Substances; D007328:Insulin; D009652:Norpregnenes; D011372:Progestins; C033273:Gestodene; D004247:DNA